Derivative works — US Patent 11013729

Defensive Disclosure: Derivative Variations of US Patent 11013729

This document outlines derivative variations of the oral pharmaceutical compositions claimed in US Patent 11013729, focusing on the core inventive concept of separating dabigatran etexilate from organic acids into distinct particle types. These disclosures aim to establish prior art for future incremental improvements by rendering them obvious or non-novel.

Core Claim Addressed: Claim 1

Claim 1 describes a composition comprising a mixture of at least two distinct types of particles: a first type comprising dabigatran etexilate (free from organic/inorganic acids) and a second type comprising at least one pharmaceutically acceptable organic acid (coated with a protective coating layer and free from dabigatran etexilate).

Derivative Variations

1. Material & Component Substitution

Derivative 1.1: Self-Emulsifying Solid Dispersion for Dabigatran Etexilate Particles

Enabling Description: The first type of particles, comprising dabigatran etexilate mesylate, is prepared as a solid self-emulsifying drug delivery system (S-SEDDS). Dabigatran etexilate mesylate is dissolved or dispersed in a mixture of pharmaceutically acceptable lipids (e.g., Capmul® MCM, Labrafil® M 1944 CS) and non-ionic surfactants (e.g., Cremophor® RH40, Tween® 80), with a hydrophilic binder (e.g., Kollidon® VA64) and a superdisintegrant (e.g., Explotab®) acting as a solid carrier. This molten mixture is spray-dried or melt-extruded onto inert spherical carriers (e.g., microcrystalline cellulose spheres) to form granules. This process ensures enhanced solubility and bioavailability by forming a fine emulsion in the gastrointestinal tract, while maintaining the acid-free characteristic of the dabigatran-containing particles. The resulting S-SEDDS granules typically have a particle size distribution of 100-500 microns.

flowchart TD
    A[Dabigatran Etexilate Mesylate] --> B(Lipids + Surfactants)
    B --> C{Homogenize & Heat}
    C --> D[Melt Mixture]
    E[Hydrophilic Binder + Superdisintegrant] --> F(Inert Spherical Carriers)
    D --Spray Dry or Melt Extrude onto--> F
    F --> G[S-SEDDS Granules]
    G --Free from Acids--> H(First Type Particles)

Derivative 1.2: Phytic Acid Coated Pellets for Acid Component

Enabling Description: The second type of particles comprises phytic acid (inositol hexakisphosphate) as the pharmaceutically acceptable organic acid. Phytic acid, known for its chelating properties and lower intrinsic water solubility compared to tartaric acid, is granulated with a suitable binder (e.g., polyvinylpyrrolidone K30) and diluent (e.g., calcium phosphate dibasic anhydrous) via wet granulation, followed by extrusion-spheronization to form spherical pellets (target size: 400-800 microns). These phytic acid pellets are then coated with a protective layer composed of a polymethacrylate copolymer (e.g., Eudragit® FS 30 D) combined with a plasticizer (e.g., triethyl citrate) and an anti-tacking agent (e.g., talc) via fluid bed coating. This coating is designed to resist gastric pH and release the phytic acid in the intestinal environment, ensuring separation from the dabigatran etexilate until appropriate physiological conditions are met, thus preventing premature hydrolysis.

graph TD
    A[Phytic Acid] --> B(Binder + Diluent)
    B --Wet Granulation--> C{Wet Mass}
    C --Extrusion-Spheronization--> D[Phytic Acid Pellets]
    E[Polymethacrylate Copolymer] --> F(Plasticizer + Anti-tacking Agent)
    F --Fluid Bed Coating--> G[Protective Coating Layer]
    D --Coated with--> G
    G --> H(Second Type Particles)
    H --Free from Dabigatran Etexilate--> I(Coated Phytic Acid Pellets)

Derivative 1.3: Cellulose Acetate Phthalate (CAP) Protective Coating

Enabling Description: The protective coating layer for the second type of particles (organic acid pellets) is formulated using cellulose acetate phthalate (CAP) as the primary film-forming polymer. CAP is dissolved in an organic solvent system (e.g., acetone/isopropyl alcohol mixture) along with a suitable plasticizer (e.g., diethyl phthalate) to ensure film flexibility. This coating solution is applied to the organic acid pellets (e.g., tartaric acid pellets) in a fluid bed coater. CAP provides an enteric coating that remains intact in acidic gastric fluid (pH < 4.5) and rapidly dissolves at higher intestinal pH, ensuring that the organic acid is released distal to the stomach, thus minimizing any potential contact with dabigatran etexilate in the upper gastrointestinal tract before the protective effect of acid is required for optimal absorption. The coating is applied to a weight gain of 5-15% by weight of the pellets.

stateDiagram
    direction LR
    State1: Organic Acid Pellet
    State2: CAP Coating Application
    State3: Drying
    State4: Coated Pellet (Gastric Stable)
    State5: Intestinal pH (~6.0)
    State6: CAP Dissolves
    State7: Organic Acid Release
    State1 --> State2: Coating Process
    State2 --> State3: Solvent Evaporation
    State3 --> State4: Formation of Protective Layer
    State4 --> State5: Ingestion & Gastric Passage
    State5 --> State6: pH Triggered Dissolution
    State6 --> State7: Controlled Release

2. Operational Parameter Expansion

Derivative 2.1: Nanoparticulate Dabigatran and Micro-Tablet Acid Components

Enabling Description: The first type of particles comprises dabigatran etexilate mesylate formulated as nanoparticles, with a mean particle size ranging from 50 nm to 200 nm, stabilized by a non-ionic surfactant (e.g., Polysorbate 80) and a polymeric stabilizer (e.g., Soluplus®) using wet media milling or high-pressure homogenization. These nanoparticles are then spray-dried with a suitable diluent (e.g., mannitol) to form flowable powder granules of 50-150 microns. The second type of particles consists of compressed micro-tablets (1 mm to 3 mm diameter) of tartaric acid blended with a disintegrant (e.g., croscarmellose sodium) and a binder (e.g., pregelatinized starch). These micro-tablets are then film-coated with a moisture-barrier polymer (e.g., ethylcellulose) to ensure stability and separation from the dabigatran nanoparticles. This combination allows for extremely rapid initial dissolution of dabigatran nanoparticles and a precisely controlled, delayed release of the acidifier.

graph LR
    A[Dabigatran Etexilate Mesylate] --> B(Nanoparticle Formation: 50-200nm)
    B --Spray Dry with Mannitol--> C[First Type Granules: 50-150µm]
    D[Tartaric Acid + Disintegrant + Binder] --> E(Micro-tablet Compression: 1-3mm)
    E --Film Coating (Ethylcellulose)--> F[Second Type Micro-tablets]
    C & F --> G{Capsule Filling: Mixture}

Derivative 2.2: Multi-Layered Enteric Coating with pH-Triggered Burst Release

Enabling Description: The second type of particles (organic acid pellets) is equipped with a multi-layered protective coating for precision pH-triggered burst release. The innermost layer is a moisture barrier (e.g., Opadry® AMB) to protect the acid core. Over this, an intermediate layer of a pH-dependent polymer (e.g., Eudragit® L 30 D-55, dissolving at pH > 5.5) is applied. The outermost layer is a rapidly dissolving polymer (e.g., hydroxypropylmethylcellulose) containing a pore-forming agent (e.g., polyethylene glycol) and an effervescent agent (e.g., sodium bicarbonate). Upon dissolution of the outermost layer in the stomach, water penetrates to the intermediate enteric layer. Once the pH environment reaches approximately 5.5-6.0 in the duodenum, the intermediate layer rapidly dissolves, and the effervescent agent instantly releases CO2, causing a rapid disintegration of the remaining coating and a burst release of the organic acid. This ensures a precisely timed acidic microenvironment for optimal dabigatran absorption.

graph TD
    A[Organic Acid Pellet] --> B(Moisture Barrier Layer)
    B --> C(pH-Dependent Enteric Layer: Eudragit L 30 D-55)
    C --> D(Rapid Dissolving Layer with Pore/Effervescent Agents)
    D --> E[Multi-Layer Coated Pellet]
    E --Gastric Passage (pH < 5.5)--> F{Outer Layer Dissolves}
    F --> G{Intermediate Layer Intact}
    G --Duodenal Passage (pH > 5.5)--> H{Intermediate Layer Dissolves & Burst Release}

Derivative 2.3: Continuous Hot-Melt Extrusion Manufacturing

Enabling Description: The manufacturing process for both particle types is implemented using continuous hot-melt extrusion (HME) technology. For the first type of particles, dabigatran etexilate mesylate is dry blended with a melt-extrudable polymer (e.g., Kollidon® VA64, Soluplus®) and a plasticizer (e.g., polyethylene glycol 6000). This blend is fed into a twin-screw extruder operating at elevated temperatures (e.g., 120-150°C) and then cooled and milled to form granules of 200-800 microns, ensuring acid-free composition. For the second type, the pharmaceutically acceptable organic acid (e.g., citric acid) is similarly melt-extruded with a melt-extrudable polymer (e.g., Ethocel™ Standard 10 Premium, Surelease®) acting as a sustained-release matrix. The resulting extrudate is then spheronized and coated in-line with a protective layer using an integrated fluid bed coater before final milling and screening, ensuring the dabigatran-free and coated properties. This HME-based approach enhances process efficiency and content uniformity.

flowchart LR
    A[Dabigatran + Polymer + Plasticizer] --> B(HME - Extruder 1)
    B --> C(Cooling & Milling)
    C --> D[Dabigatran Granules (First Type)]
    E[Organic Acid + Polymer] --> F(HME - Extruder 2)
    F --> G(Spheronization)
    G --> H(In-line Fluid Bed Coater)
    H --> I[Coated Acid Pellets (Second Type)]
    D & I --> J{Blending & Encapsulation}

3. Cross-Domain Application

Derivative 3.1: Soil Amendment for Nutrient Release in AgTech

Enabling Description: A soil amendment composition designed to optimize nutrient availability for plants in pH-sensitive environments. The first type of particles contains a pH-sensitive micronutrient (e.g., iron chelate that becomes insoluble at high pH) stabilized with a non-acidic polymer matrix (e.g., starch-based biodegradable polymer), with a particle size of 200-1000 microns, ensuring the iron chelate is not immediately exposed to acid. The second type of particles comprises a slow-release organic acid (e.g., humic acid or fulvic acid embedded in a lignin-based hydrophobic coating), also with a particle size of 200-1000 microns. This protective coating prevents premature acid release. When applied to alkaline soils, moisture penetrates the coated acid particles over time, slowly releasing the acid to create localized acidic microenvironments, which solubilize the micronutrient from the first type of particles, making it bioavailable to plant roots.

graph TD
    A[pH-Sensitive Micronutrient] --> B(Non-Acidic Polymer Matrix)
    B --> C[Nutrient Particles (First Type)]
    D[Humic/Fulvic Acid] --> E(Lignin-based Hydrophobic Coating)
    E --> F[Acid Particles (Second Type)]
    C & F --> G{Soil Application Mixture}
    G --Moisture Penetration (Slow)--> H{Acid Release (Localized)}
    H --> I{Micronutrient Solubilization}

Derivative 3.2: Oral Vaccine Delivery for Aquatic Animals

Enabling Description: An oral vaccine delivery system for aquatic animals (e.g., fish in aquaculture) targeting enteric pathogens. The first type of particles contains a live attenuated vaccine strain (e.g., bacterial antigens) encapsulated in an alginate-chitosan matrix that is free from organic acids. The second type of particles contains a feed-grade organic acid (e.g., formic acid salt, e.g., sodium formate) incorporated into a lipid-based pellet and coated with a gastric-resistant polymeric coating (e.g., shellac or zein). These coated acid particles are designed to release the acid upon reaching the posterior gut, creating an acidic environment conducive to the stability and uptake of the live vaccine, which is released from the first type of particles as the alginate-chitosan matrix degrades, thereby bypassing gastric degradation.

sequenceDiagram
    participant Fish as Fish Intestine
    actor Pellet as Mixed Pellets
    Pellet->>Fish: Ingestion
    Fish->>Pellet: Gastric Passage
    Pellet->>Acid_Particle: Gastric Resistant Coating Intact
    Pellet->>Vaccine_Particle: Alginate-Chitosan Matrix Intact
    Fish->>Acid_Particle: Posterior Gut pH
    Acid_Particle->>Acid_Particle: Coating Dissolves
    Acid_Particle->>Acid_Particle: Formic Acid Release
    Acid_Particle-->>Vaccine_Particle: Local Acidification
    Vaccine_Particle->>Vaccine_Particle: Alginate-Chitosan Degradation
    Vaccine_Particle->>Fish: Vaccine Antigen Release & Uptake

Derivative 3.3: Humidity-Activated Deodorizer for Consumer Electronics

Enabling Description: A humidity-activated deodorizing insert for consumer electronics (e.g., internal components of air purifiers or humidifiers). The first type of particles comprises a pH-sensitive malodor adsorbate or neutralizing agent (e.g., certain metal oxides or amines) encapsulated in a moisture-permeable but acid-free polymer. The second type of particles contains an encapsulated organic acid (e.g., citric acid encapsulated in a hygroscopic, slow-dissolving polymer like polyvinyl alcohol) with a protective coating. In high-humidity conditions (e.g., inside an operating humidifier), the coating on the acid particles slowly dissolves, releasing the organic acid, which then interacts with the acid-sensitive malodor adsorbate particles. This interaction (e.g., pH change, direct chemical reaction) enhances the deodorizing capacity of the first particle type, providing an on-demand, humidity-controlled odor neutralization system without premature activation in dry conditions.

stateDiagram
    direction LR
    State1: Dry Environment
    State2: High Humidity
    State3: Acid Coating Dissolves (Slowly)
    State4: Organic Acid Release
    State5: Adsorbate/Neutralizer Particles
    State6: Enhanced Deodorization
    State1 --> State5: Dormant
    State1 --> State2: Humidity Increase
    State2 --> State3: PVA Coating Activation
    State3 --> State4: Citric Acid Release
    State4 --> State6: Interaction with State5
    State5 --> State6: Increased Activity

4. Integration with Emerging Tech

Derivative 4.1: AI-Optimized Fluid Bed Granulation and Coating

Enabling Description: An autonomous manufacturing system for the dabigatran etexilate composition, leveraging AI-driven optimization. The fluid bed granulation (for dabigatran particles) and fluid bed coating (for organic acid pellets) processes are equipped with in-line process analytical technology (PAT) sensors including NIR spectroscopy for active pharmaceutical ingredient (API) content and moisture, laser diffraction for real-time particle size distribution, and acoustic sensors for granule morphology. Data from these sensors are continuously fed into a predictive AI model (e.g., a recurrent neural network) that has been trained on historical batch data and optimal dissolution profiles. The AI model dynamically adjusts critical process parameters (e.g., spray rate, atomization pressure, inlet air temperature, bed height, and coating solution viscosity) in real-time, within predefined quality by design (QbD) parameters, to maintain optimal product quality, minimize waste, and ensure consistent in-vitro release characteristics without human intervention for fine adjustments.

flowchart TD
    A[Raw Materials] --> B(Fluid Bed Granulator/Coater)
    B --In-line PAT Sensors--> C{Real-time Data Stream}
    C --> D[AI Optimization Engine]
    D --Parameter Adjustment Feedback--> B
    B --> E[Optimized Particle Output]
    E --> F{Final Blending & Encapsulation}
    D --Predictive Analytics & Model Update--> G(Data Lake/Historical Data)

Derivative 4.2: IoT-Enabled Smart Capsule for In-Vivo Monitoring

Enabling Description: The oral pharmaceutical composition is delivered via an IoT-enabled "smart capsule." The organic acid pellets are individually embedded with micro-pH sensors (e.g., miniaturized solid-state ion-selective field-effect transistors, ISFETs) and a micro-transmitter, powered by a biocompatible micro-battery. Upon ingestion, these sensors continuously monitor the pH conditions within the gastrointestinal tract at the point of acid release. The first type of particles (dabigatran etexilate) remains acid-free. The real-time pH data, along with location data (if using ingestible RFID or localization technologies), is wirelessly transmitted to an external wearable receiver or smartphone application. This allows for precise, patient-specific correlation of acid release timing with physiological pH, enabling physicians to tailor dosing regimens or dietary advice based on individual gastric emptying and intestinal transit times, and potentially detect malabsorption issues.

classDiagram
    class Smart_Capsule {
        +DabigatranParticles
        +CoatedAcidPellets
    }
    class CoatedAcidPellets {
        +OrganicAcid
        +ProtectiveCoating
        +MicroPHSensor
        +MicroTransmitter
        +MicroBattery
    }
    class ExternalReceiver {
        +WirelessAntenna
        +DataLogger
        +SmartphoneAppInterface
    }
    Smart_Capsule "1" -- "N" CoatedAcidPellets : contains
    CoatedAcidPellets <.. ExternalReceiver : Transmits pH data
    ExternalReceiver <.. Patient : Personalized Feedback

Derivative 4.3: Blockchain-Verified Ingredient Traceability

Enabling Description: A comprehensive blockchain-based system is deployed to ensure the integrity and traceability of all raw materials (dabigatran etexilate mesylate, organic acid, excipients, coating polymers) and the finished two-particle pharmaceutical composition. Each lot of raw material is assigned a unique cryptographic hash and registered on a private or consortium blockchain. Smart contracts automatically update the ledger at each stage of the supply chain (e.g., supplier, manufacturer, distributor, pharmacy). Quality control data (e.g., Certificates of Analysis, PAT data from Derivative 4.1) are also hashed and immutably linked to their respective material lots on the blockchain. Environmental monitoring data from IoT sensors during storage and transit (temperature, humidity, light exposure) are recorded as transactions. This provides an incorruptible audit trail, verifying the authenticity of each component, preventing counterfeiting, ensuring compliance with storage conditions, and enabling rapid recall if any quality deviations are detected.

flowchart TD
    A[Raw Material Supplier] --> B{Cryptographic Hashing & Blockchain Entry}
    B --> C[Manufacturing Plant]
    C --QC Data & Process Records--> D{Smart Contract Update}
    D --> E[Distribution Center]
    E --IoT Environmental Data--> F{Smart Contract Update}
    F --> G[Pharmacy/Hospital]
    G --> H[Patient]
    subgraph Blockchain Network
        B---D---F
    end

5. The "Inverse" or Failure Mode

Derivative 5.1: pH-Induced Self-Degradation for Safety

Enabling Description: A safety mechanism integrated into the dabigatran etexilate particles to induce controlled degradation under highly acidic conditions, preventing toxic accumulation in cases of accidental exposure or extreme physiological anomalies. The dabigatran etexilate particles (first type, acid-free) are formulated with a pH-sensitive auxiliary excipient (e.g., a small percentage of a basic polymer like polyethylenimine or an insoluble salt like magnesium oxide) finely dispersed within the granule. If these particles are prematurely exposed to an extremely low pH environment (e.g., pH < 1.0, indicative of a severe gastric upset or direct acid contact), the auxiliary excipient dissolves or reacts, creating localized microenvironments within the dabigatran particles that significantly accelerate the known hydrolytic degradation pathways of dabigatran etexilate into inactive metabolites. This "self-destruct" mechanism ensures that in potentially harmful, off-label exposure scenarios, the active drug is rapidly rendered inert, preventing systemic absorption of an uncontrolled dose.

stateDiagram
    direction LR
    State1: Dabigatran Particle (Normal)
    State2: Exposure to Extreme Low pH (<1.0)
    State3: Auxiliary Excipient Reacts/Dissolves
    State4: Localized Microenvironment pH Shift
    State5: Accelerated Dabigatran Hydrolysis
    State6: Inactive Metabolites
    State1 --> State2: Aberrant Condition
    State2 --> State3: Trigger
    State3 --> State4: Cascade
    State4 --> State5: Degradation Path
    State5 --> State6: Safe Outcome

Derivative 5.2: Humidity-Triggered Low-Dose Release

Enabling Description: The pharmaceutical composition is engineered to automatically adjust the release profile to a lower effective dose under conditions of high ambient humidity, anticipating potential moisture-induced degradation or altered patient physiology in humid climates. The protective coating on the organic acid pellets (second type) is designed with a hygroscopic, semi-permeable polymer (e.g., a blend of ethylcellulose and a high-molecular-weight polyethylene glycol) that becomes significantly more permeable to water vapor above a critical relative humidity (e.g., >75% RH). In such high-humidity storage conditions, water penetrates the coating at an accelerated rate, causing a partial or slower release of the organic acid over an extended period. This slower acid release, in turn, leads to a delayed or attenuated overall dissolution rate of dabigatran etexilate in vivo, effectively delivering a "low-power" or reduced functional dose. This mechanism acts as an inherent safety feature, potentially mitigating the risk of over-exposure if the product's stability or patient's metabolic capacity is compromised in tropical or highly humid environments.

stateDiagram
    direction LR
    State1: Coated Acid Pellet (Normal)
    State2: High Ambient Humidity (>75% RH)
    State3: Hygroscopic Coating Permeability Increases
    State4: Water Ingress into Pellet (Accelerated)
    State5: Slower Organic Acid Release Profile
    State6: Attenuated Dabigatran Dissolution (In Vivo)
    State7: Lower Effective Dose
    State1 --> State2: Environmental Trigger
    State2 --> State3: Coating Response
    State3 --> State4: Water Absorption
    State4 --> State5: Acid Release Modification
    State5 --> State6: Downstream Impact
    State6 --> State7: Functional Adjustment

Combination Prior Art Scenarios with Open-Source Standards

These scenarios illustrate how the inventive composition, as described in US11013729, can be combined with existing open-source pharmaceutical standards, making any claims encompassing these standard practices obvious.

1. Combination with USP <711> Dissolution Testing Standards

Scenario: A pharmaceutical composition comprising the two distinct particle types of dabigatran etexilate and a pharmaceutically acceptable organic acid, formulated into a capsule, wherein the dissolution profile of said composition is characterized and controlled according to the procedures outlined in the United States Pharmacopeia (USP) General Chapter <711> Dissolution. Specifically, the composition demonstrates a dissolution rate of not less than 60% of dabigatran etexilate mesylate released within 15 minutes when tested in 0.01N HCl pH 2.0 dissolution media at 37±0.5°C using a USP Apparatus 1 (basket apparatus) at a stirring speed of 100 revolutions per minute (rpm), with samples analyzed by UV-Vis spectrophotometry or High-Performance Liquid Chromatography (HPLC) in compliance with USP analytical methods.

2. Combination with ICH Q1A(R2) Stability Testing Guidelines

Scenario: A chemically and polymorphically stable oral pharmaceutical composition containing a mixture of the two distinct particle types (dabigatran etexilate-containing and coated organic acid-containing particles), prepared and packaged to demonstrate stability consistent with the International Council for Harmonisation (ICH) Q1A(R2) guideline on stability testing of new drug substances and products. This includes conducting accelerated stability studies at 40°C/75% relative humidity (RH) for 6 months and long-term stability studies at 25°C/60% RH or 30°C/65% RH for at least 12 months. Stability parameters such as assay of dabigatran etexilate, levels of degradation products (e.g., hydrolytic impurities), dissolution profiles, moisture content, and polymorphic form are monitored at specified time points using validated analytical methods compliant with ICH M10 (Bioanalytical Method Validation).

3. Combination with ISO 13320 (Particle Size Analysis - Laser Diffraction Methods)

Scenario: A pharmaceutical composition containing two distinct types of particles, where the first type of particles (comprising dabigatran etexilate) and the second type of particles (comprising a pharmaceutically acceptable organic acid) are characterized for their particle size distribution using laser diffraction, in accordance with the International Organization for Standardization (ISO) 13320:2020 standard. The particle size distribution of both particle types (e.g., D10, D50, D90 values) is determined by dispersing samples in a suitable non-solubilizing liquid (e.g., mineral oil or isopropyl alcohol for dry powders/granules) with appropriate sonication and stirring, and analyzed using either Fraunhofer or Mie scattering theories, depending on particle opacity and size range, to ensure compliance with predefined specifications for optimal processing and in-vivo performance.